Document:

EX-10.z

 Exhibit 10z 
 *Confidential Treatment Requested 
  

 
 AMENDED AND RESTATED 

TERRITORY B1 PRODUCT KNOW-HOW LICENSE AGREEMENT 
 among 
 SANOFI 

BRISTOL-MYERS SQUIBB COMPANY 
 and 
 SANOFI-AVENTIS U.S. LLC 

dated as of January 1, 2013 
  

 
 *CONFIDENTIAL TREATMENT REQUESTED.
CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 TABLE OF CONTENTS 

 

							
		 	ARTICLE 1	  			
		 	DEFINITIONS	  			
			
	 1.1
	 	Defined Terms	  	 	2	  
	 1.2
	 	Additional Defined Terms	  	 	4	  
		 	ARTICLE 2	  			
		 	GRANT OF LICENSE	  			
			
	 2.1
	 	License Grant	  	 	5	  
	 2.2
	 	No Transfer	  	 	5	  
	 2.3
	 	No Implicit Rights	  	 	5	  
	 2.4
	 	Original License	  	 	5	  
	 2.5
	 	Corporate Name Authorization	  	 	5	  
		 	ARTICLE 3	  			
		 	SUB-LICENSE	  			
			
	 3.1
	 	General Sub-License	  	 	5	  
	 3.2
	 	Termination of Sub-License	  	 	6	  
		 	ARTICLE 4	  			
		 	CONSIDERATION	  			
			
	 4.1
	 	Development Royalty	  	 	6	  
	 4.2
	 	Payment	  	 	6	  
	 4.3
	 	Method of Payment	  	 	6	  
	 4.4
	 	Records	  	 	6	  
	 4.5
	 	Taxes	  	 	7	  
		 	ARTICLE 5	  			
		 	TERM; TERMINATION	  			
			
	 5.1
	 	Term; Termination	  	 	7	  
	 5.2
	 	Consequences of Termination	  	 	8	  
		 	ARTICLE 6	  			
		 	CONFIDENTIALITY	  			
			
		 	ARTICLE 7	  			
		 	MISCELLANEOUS	  			
			
	 7.1
	 	Notices	  	 	8	  
	 7.2
	 	Governing Law	  	 	10	  
	 7.3
	 	Dispute Resolution	  	 	10	  
	 7.4
	 	Specific Performance	  	 	11	  
	 7.5
	 	No Third Party Beneficiaries	  	 	11	  
	 7.6
	 	Assignment	  	 	11	  
	 7.7
	 	Severability	  	 	12	  
	 7.8
	 	Waivers and Amendments	  	 	12	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 i 

							
	 7.9   Headings
	  	 	12	  
	 7.10 Entire Agreement
	  	 	12	  
	 7.11 No Partnership or Joint Venture
	  	 	12	  
	 7.12 Governing Language
	  	 	13	  
	 7.13 Counterparts
	  	 	13	  
	 7.14 Force Majeure
	  	 	13	  
	 7.15 Definitive Agreement
	  	 	13	  
		
	SCHEDULES	  		

 SCHEDULE 1A TERRITORY B1 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 ii 

 This AMENDED AND RESTATED TERRITORY B1 PRODUCT KNOW-HOW LICENSE AGREEMENT (this
“Agreement”) dated as of January 1, 2013 is hereby made by and among: 
 Sanofi, a
société anonyme organized and existing under the laws of the French Republic (“Sanofi”); 

Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware, United States of America
(“BMS”); and 
 sanofi-aventis U.S. LLC, a Delaware limited liability company (the “Licensee”
and, together with Sanofi and BMS, the “Parties” and, individually, each a “Party”). 
 W
I T N E S S E T H: 
 WHEREAS, Sanofi previously discovered and patented two new chemical entities, one known as SR
47436 with the international non-proprietary name Irbesartan (“Irbesartan”) and one known as SR 25990C with the international non-proprietary name Clopidogrel Hydrogenosulphate (“Clopidogrel”); 

WHEREAS, Sanofi, BMS and Sterling Winthrop Inc., a Delaware corporation (“Sterling”) entered into a Development
Agreement dated July 29, 1993 (the “Development Agreement”) for, among other things, the development of Irbesartan and Clopidogrel; 
 WHEREAS, pursuant to an Amended and Restated Asset Purchase Agreement dated as of September 30, 1994 among Eastman Kodak Company, Sanofi and Sterling, Sanofi acquired certain assets, and assumed
certain obligations, of the ethical pharmaceutical business of Sterling, including the rights and obligations of Sterling under the Development Agreement; 
 WHEREAS, Sanofi and BMS have formed through their indirect wholly owned subsidiaries Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, a Delaware partnership (the
“Partnership”) for, among other things, the commercialization of the Products in certain territories, including Territory B1 (as such terms are defined herein); 

WHEREAS, Sanofi and the Partnership have entered into an Irbesartan Intellectual Property License Agreement and a Clopidogrel
Intellectual Property License and Supply Agreement, each dated as of January 1, 1997 and amended as of the date hereof (the “Territory B License Agreements”), pursuant to which Sanofi granted to the Partnership a license to use
certain patents, trademarks and know-how for the commercialization of the Products in certain territories, including Territory B1, that neither were developed with nor are owned by BMS; 

WHEREAS, Sanofi and BMS have developed certain know-how under the Development Agreement for the commercialization of the Products and, as
a result, each has an undivided one-half direct ownership interest in the Developed Know-How (as such term is defined herein); 

*CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 WHEREAS, Sanofi, BMS and the Partnership have entered into a Product Know-How License
Agreement dated as of January 1, 1997 (the “Original License”), pursuant to which Sanofi and BMS granted to the Partnership a license under the Developed Know-How for the commercialization of the Products in certain
territories, including Territory B1; 
 WHEREAS, pursuant to the Master Restructuring Agreement (the “Definitive
Agreement”), dated as of September 27, 2012, by and between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to the Products, other than
Clopidogrel in the United States; and 
 WHEREAS, in connection with the transactions contemplated by the Definitive Agreement,
Sanofi and BMS have agreed to, among other things, (i) assign the Territory B License Agreements from the Partnership to the Licensee, solely with respect to Territory B1, (ii) assign the Original License from the Partnership to the
Licensee, solely with respect to Territory B1, (iii) amend and restate such assigned Territory B License Agreements and (iv) amend and restate such assigned Original License on the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants and the terms and conditions set forth herein, the Parties hereby agree as
follows: 
 ARTICLE 1 
 DEFINITIONS 
 1.1 Defined Terms. As used in this Agreement, the
following terms shall have the following meanings: 
 “Affiliate”, when used with reference to any Person, means
any other Person controlling, controlled by, or under common control with, such Person; provided, however, that, with respect to Sanofi, the definition of Affiliate shall exclude L’Oréal, a societe anonyme organized and
existing under the laws of the French Republic. For the purposes of this definition, “control” shall refer to (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person or to veto
any material decision relating to the management or policies of a Person, in each case whether through the ownership of voting securities, by contract or otherwise, (b) the beneficial ownership, directly or indirectly, of securities (excluding
general partnership interests) representing at least 50% of the voting power of all outstanding voting securities of a Person or (c) the beneficial ownership of at least 50% of the partnership interests of a general partnership. 

“Clopidogrel Product” means (i) a product with the sole active ingredient Clopidogrel, in
finished form, marketed under the trademarks Plavix® and
Iscover® or any trademark that is confusingly similar to or that is a replacement for any such trademark, and
(ii) a product (an “Identified Clopi FDC”) which contains as the only active ingredients the combination of Clopidogrel with acetylsalicylic acid, in finished form, marketed under the trademarks DuoPlavin®, DuoCover® and CoPlavix® or any
trademark that is confusingly similar to or that is a replacement for any such trademark. For the avoidance of doubt, Clopidogrel Products shall exclude any Fixed Dose Combination Products. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 2 

 “Designated Exchange Rate” means the exchange rate applicable for each
calendar month based on the prior month’s daily average EUR/USD rate set by the European Central Bank each day. 

“Developed Know-How” means any and all technical data, information, material and other know-how that relate to the
formulation of the Products, including, without limitation, any analytical methodology, chemical, toxicological, pharmacological and clinical data, formulae, procedures, protocols, techniques and results of experimentation and testing, developed by
Sanofi and BMS under the Development Agreement. 
 “fixed dose combination” means a pharmaceutical dosage form
containing fixed doses of more than one active ingredient in which all active ingredients are present in a single tablet, capsule or other form and shall expressly exclude so-called “co-packaging” in which separate drugs in separate dosage
forms are sold in a single unit or bundle. 
 “Fixed Dose Combination Product” means a fixed dose combination
containing Clopidogrel or Irbesartan (other than the Identified Clopi FDCs and the Identified Irbe FDCs). 

“Governmental Authority” means any federal, state or local or any foreign or supranational government, governmental,
regulatory or administrative authority, agency or commission or any court, tribunal or judicial or arbitral body. 

“Identified Clopi FDC” has the meaning set forth in the definition of Clopidogrel Product. 

“Identified Irbe FDC” has the meaning set forth in the definition of Irbesartan Product. 

“IFRS Net Sales” means, with respect to a Product, net sales of Sanofi (or its Affiliates or their respective licensees
or sublicensees) as audited and reported in Euros by Sanofi (or its Affiliates or licensees) in accordance with International Financial Reporting Standards (“IFRS”), as IFRS may be modified from time to time. For the avoidance of
doubt: (a) IFRS Net Sales shall not include samples, compassionate use of the Products and the like; provided that revenue from Products sold to third parties for clinical trial purposes shall be included in IFRS Net Sales; and
(b) any Damages (as defined in the Definitive Agreement) paid by Sanofi pursuant to Article IX of the Definitive Agreement shall not be treated as a deduction for purposes of calculating IFRS Net Sales. In calculating IFRS Net Sales, the
Parties shall disregard any related Know-How, Discovery or other royalties paid to Sanofi after January 1, 2013 on Clopidogrel Products or Irbesartan Products. 

“Irbesartan Product” means: (a) a product with the sole active ingredient Irbesartan, in
finished form, marketed under the trademarks Aprovel®, Karvea® and Avapro® or any trademark
that is confusingly similar to or that is a replacement for any such trademark; and (b) a product (an “Identified Irbe FDC”) which contains as the only active ingredients the combination of Irbesartan with Hydrochlorothiazide,
in finished form, marketed under the trademarks CoAprovel®, Avalide® and Karvezide® or any trademark that is confusingly similar to or that is a replacement for any such trademark. For the avoidance of doubt, Irbesartan Products shall exclude any
Fixed Dose Combination Products. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 3 

 “New IP Agreement” means the FDC Intellectual Property License Agreement
between Sanofi and BMS, dated as of the date hereof. 
 “Person” means any individual, partnership, firm,
corporation, société anonyme, société en nom collectif, société en participation, société par actions simplifiée, limited liability company, joint venture, association, trust or
other entity or any government or any agency or political subdivision thereof, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the U.S. Securities Exchange Act of 1934, as amended. 

“Product” means a Clopidogrel Product or an Irbesartan Product and “Products” means both a Clopidogrel
Product and an Irbesartan Product. 
 “Territory B1” means the countries and geographic areas described and
listed in Schedule 1A attached hereto. 
 “Third Party” means a Person who or which is neither a Party
nor an Affiliate of a Party. 
 “United States” means any State or Commonwealth of the United States of
America, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa and any other territory, possession or military base of the United States of America. 

1.2 Additional Defined Terms. The following additional defined terms shall have the meanings set forth in the sections of this
Agreement listed below: 
  

			
	 Defined Term
	  	Section Where Defined
	 Agreement
	  	Preamble
	 BMS
	  	Preamble
	 Clopidogrel
	  	Recitals
	 Definitive Agreement
	  	Recitals
	 Development Agreement
	  	Recitals
	 Development Royalty
	  	4.1
	 Dispute
	  	7.3
	 Dispute Resolution Notice
	  	7.3
	 Force Majeure
	  	7.14
	 Irbesartan
	  	Recitals
	 ICC
	  	7.3
	 Licensee
	  	Preamble
	 License Termination Date
	  	5.2
	 Notices
	  	7.1
	 Original License
	  	Recitals
	 Partnership
	  	Recitals
	 Party
	  	Preamble
	 Sanofi
	  	Preamble
	 Sterling
	  	Recitals
	 Territory B License Agreements
	  	Recitals

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 4 

 ARTICLE 2 
 GRANT OF LICENSE 
 2.1 License Grant. Subject to the terms and
conditions of this Agreement, Sanofi and BMS each separately grant to the Licensee an exclusive license for the term hereof in their respective undivided one-half direct ownership interest in the Developed Know-How, and the Licensee hereby accepts,
an exclusive license for the term hereof under the Developed Know-How, to make, have made, sell, offer for sale and import the Products in Territory B1, provided that the foregoing exclusivity shall not apply to Sanofi and BMS to the
extent of their respective rights under the New IP Agreement with respect to Fixed Dose Combination Products, and each of Sanofi and BMS retain all of their respective rights under the Developed Know-How with respect to Fixed Dose Combination
Products, subject to the licenses granted under the New IP Agreement. 
 2.2 No Transfer. The Licensee hereby
acknowledges and agrees that this Agreement does not, and shall not be deemed to, transfer any proprietary ownership interest whatsoever to the Licensee in or to the Developed Know-How. Nothing herein shall give the Licensee any right, title or
interest in or to any of the Developed Know-How, except the rights granted pursuant to this Agreement. 
 2.3 No Implicit
Rights. All of the rights granted hereunder are explicitly stated herein and nothing in this Agreement shall be construed to grant any implied rights whatsoever to the Licensee in or to the Developed Know-How. 

2.4 Original License. The Parties hereby agree that all acts, omissions and occurrences prior to the date hereof, and all rights
and obligations of the Parties with respect thereto, shall be governed by the terms of the Original License prior to its amendment and restatement in accordance with the terms hereof. 

2.5 Corporate Name Authorization. The Licensee, Sanofi and its Affiliates shall be permitted to use the BMS Brands (as defined in
the Definitive Agreement) pursuant to and in accordance with Section 7.1 of the Definitive Agreement. 
 ARTICLE 3

 SUB-LICENSE 
 3.1 General Sub-License. The Licensee shall have the right to sub-license any of its rights and obligations under this Agreement to any Person, including, without limitation, any Affiliate of
Sanofi, provided that, each sub-licensee shall be subject to, and comply fully with, the applicable provisions of this Agreement including, without limitation, Article 6 hereof. No such sub-license shall relieve the Licensee of its
obligations hereunder. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 5 

 3.2 Termination of Sub-License. Sanofi and BMS each shall have the right to require
the Licensee to terminate any sub-license of rights hereunder in the event that the sub-licensee fails to comply in any material respect with, or takes any action contrary to, the terms of such sub-license, and such sub-licensee has failed to remedy
such non-compliance within thirty (30) days from its receipt of written notice thereof from Sanofi, BMS or the Licensee. 

ARTICLE 4 

CONSIDERATION 
 4.1 Development Royalty. In consideration of the rights and licenses granted hereunder, the Licensee shall pay, or shall cause to be paid, for the term of this Agreement the following aggregate
amounts as a development royalty (each a “Development Royalty”), provided that, with respect to BMS, such royalty payments shall cease as of December 31, 2018 and the licenses granted by BMS to the Licensee under this
Agreement shall become [*] and [*] as of such date: 
 (i) To [*], an amount equal to [*] of IFRS Net Sales of
Irbesartan Products in Territory B1; and 
 (ii) To [*], an amount equal to [*] of IFRS Net Sales of Clopidogrel
Products in Territory B1. 
 4.2 Payment. For the term of this Agreement, the Licensee shall pay or cause to be paid to
each of Sanofi and BMS all amounts due hereunder on a quarterly basis within sixty (60) days of the end of each calendar quarter. Each such payment shall be accompanied by an accurate statement of the amount of IFRS Net Sales of the Products in
Territory B1, broken down Product-by-Product, during such calendar quarter and the calculation of all payments to be made to each of Sanofi and BMS for such calendar quarter. 
 4.3 Method of Payment. (a) All payments to be made hereunder shall be made by wire transfer in immediately available funds to the respective bank accounts of Sanofi and BMS as notified to the
Licensee by the relevant Party, unless the Parties agree to settle such payments through other means. 
 (b) Payments to be made
to BMS hereunder shall be declared in Euros based on IFRS Net Sales and shall be paid to BMS in USD and converted from Euros to USD at the Designated Exchange Rate applicable for the month in which payment is made. 

4.4 Records. The Licensee shall maintain (i) books, records and accounts which accurately and fairly reflect, in reasonable
detail, the IFRS Net Sales of the Products in Territory B1 and (ii) an adequate system of internal accounting controls. All books, records and accounts referred to in clause (i) above shall be maintained for not less than [*] or for such
longer period if and as required by applicable law, following the date of the sales constituting the IFRS Net Sales and shall be made available for reasonable review upon request by Sanofi and/or BMS. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 6 

 4.5 Taxes. All payments due under this Agreement shall be paid in full without
deduction, except for taxes (if any) required to be withheld by applicable law in Territory B1 with respect to such payments. In the event the Licensee is required under applicable law to withhold any tax to the revenue authorities in any country in
Territory B1 regarding any payment to Sanofi and/or BMS, the amount of such tax shall be deducted by the Licensee and paid to the relevant revenue authority, and the Licensee shall notify the relevant Party thereof and shall promptly furnish to such
Party all copies of any tax certificate or other documentation evidencing such withholding. In the event that any such tax shall subsequently be found to be due, payment of such tax shall be the responsibility of Sanofi or BMS, as the case may be.

 ARTICLE 5 
 TERM; TERMINATION 
 5.1 Term; Termination. (a) The term of this
Agreement, with respect to each Product, shall commence on the date hereof and shall expire on December 31, 2018. Thereafter, the term of this Agreement shall be automatically renewed for successive three-year terms, respectively. 

(b) The Parties may cause the early termination of this Agreement by the mutual written consent of each of the Parties. 

(c) Either BMS or Sanofi shall have the right to declare termination of this Agreement upon Notice to the other Parties, following the
first to occur of: 
 (i) such other Party shall have (A) voluntarily commenced any proceeding or filed any
petition seeking relief under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy, insolvency or similar law of the United States, any state thereof, the
French Republic or any other applicable jurisdiction, (B) applied for or consented to the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its
property, (C) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (D) made a general assignment for the benefit of creditors of all or substantially all of its assets,
(E) become unable generally, or admitted in writing its inability to, pay all or substantially all of its debts as they become due or (F) taken corporate action for the purpose of effecting any of the foregoing; or 

(ii) an involuntary proceeding shall have been commenced or any involuntary petition shall have been filed in a court of
competent jurisdiction seeking (A) relief in respect of such other Party, or of its property, under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy,
insolvency or similar law of the United States, any state thereof, 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 7 

 
the French Republic or any other applicable jurisdiction, (B) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other
Party or for all or substantially all of its property or (C) the winding-up or liquidation of such other Party; and such proceeding or petition shall have continued undismissed for sixty (60) days or an order or decree approving or
ordering any of the foregoing shall have continued unstayed and in effect for thirty (30) days. 
 5.2 Consequences of
Termination. (a) Upon the expiration or early termination of this Agreement pursuant to Section 5.1 hereof (the “License Termination Date”): 

(i) the Licensee shall cease, and shall cause each sub-licensee (if any) to cease, all activities related to the Developed
Know-How; and 
 (ii) the Licensee shall pay in full all amounts due to Sanofi and/or BMS hereunder within ten
(10) days after the final determination of IFRS Net Sales for such period, including the License Termination Date, pursuant to Sections 4.2, 4.3 and 4.5 hereof which shall survive until the full payment of all amounts under this clause (ii).

 (b) Expiration or early termination of this Agreement pursuant to this Article 5 shall be without prejudice to any rights
which shall have accrued to the benefit of any Party prior to such expiration or termination. Such expiration or termination shall not relieve any Party from its obligations which are expressly indicated to survive the expiration or termination of
this Agreement. All of the Parties’ rights and obligations under this subclause (b) and under Sections 4.4, 4.5, 5.2 and 7.2—7.4 and Article 6 hereof shall survive such expiration or termination for the applicable period. 

ARTICLE 6 

CONFIDENTIALITY 
 All of the data, material and information exchanged by the Parties hereunder or related hereto (including, without limitation, the Developed Know-How) shall be subject to the confidentiality provisions of
the Definitive Agreement as set forth in Section 8.8 thereof. 
 ARTICLE 7 

MISCELLANEOUS 
 7.1 Notices. All notices, requests or other communications hereunder (collectively, “Notices”) shall be in writing, shall be in the English language, and shall be given or made by
delivery in person, by courier service, by facsimile (with receipt confirmed) or by registered or certified mail (return receipt requested, with postage prepaid) to the respective Parties at the following addresses: 

If to Sanofi, to: 
 Sanofi 
 54, rue la Boétie 

75008 Paris, France 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 8 

 Attention: Senior Vice President, Legal Affairs and General Counsel

 Facsimile: (33.1) 53.77.43.03 

Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 
 with a copy to: 
 Weil Gotshal & Manges 

767 Fifth Avenue 
 New York NY 10153 
 Attention: [omitted] 

Facsimile: 212 310 8007 
 If to BMS, to: 
 Bristol-Myers Squibb Company 

P.O. Box 4000 
 Route 206 & Province Line Road 
 Princeton, NJ 08543-4000
USA 
 Attention: Vice President and Associate General Counsel, Transactional Practice Group 

Facsimile: (1-609) 252-7680 
 with a copy to: 
 Wilmer Cutler Pickering Hale and Dorr LLP

 7 World Trade Center 
 250 Greenwich Street 
 New York, NY 10007 USA 

Attention: [omitted] 
 Facsimile (212) 230-8888 
 If to the Licensee, to: 

sanofi-aventis U.S. LLC 
 55 Corporate Drive 
 Bridgewater, NJ 08807 USA 

Attention: [omitted] 
 Facsimile: (908) 981-5705 
 with a copy to: 

[omitted] 
 General Counsel, North America 
 sanofi-aventis U.S. LLC

 55 Corporate Drive 
 Bridgewater, NJ 08807 
 Fax: (908) 981-7833 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 9 

 and: 

Sanofi 
 54, rue la Boétie 
 75008 Paris, France 

Attention: Senior Vice President, Legal Affairs and General Counsel 

Facsimile: (33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 
 or to such other address or facsimile number as hereafter shall be furnished as provided in this Section 7.1 by any Party hereto to the other Parties hereto. All Notices given to any Party in
accordance with this Section 7.1 shall be deemed to have been given on the date of receipt if delivered by hand or overnight courier service or sent by facsimile, or on the date ten (10) business days after dispatch by certified or
registered mail (postage prepaid) if mailed. 
 7.2 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, United States of America, without regard to the choice of law principles that might otherwise be applied in such jurisdiction. 

7.3 Dispute Resolution. 
 (a) Negotiation and Notice. In the event of any dispute, claim, controversy or disagreement (each, a “Dispute”) arising out of, in connection with or relating to this Agreement
including any question regarding this Agreement’s existence, validity or termination, the Parties shall first seek resolution of such Dispute by negotiation between their respective senior management. Such negotiation shall be deemed to
commence upon the service by either Sanofi or BMS upon the other of a written notice (a “Dispute Resolution Notice”) under this Section 7.3(a). 
 (b) If a Dispute subject to negotiation under Section 7.3(a) is not finally resolved within thirty (30) days following receipt by either Sanofi or BMS of a Dispute Resolution Notice, the
Dispute shall be finally resolved by arbitration under the Rules of Arbitration of the International Chamber of Commerce (the “ICC”). The arbitral tribunal shall be composed of three (3) arbitrators. Each of Sanofi and BMS
shall nominate one (1) arbitrator. The two (2) arbitrators so nominated shall nominate the presiding arbitrator. If either Sanofi or BMS fails to nominate an arbitrator in its Request for Arbitration or within thirty (30) days of
receiving written notice of the nomination of an arbitrator by the other Party, such arbitrator shall be appointed by the ICC Court. If the two (2) arbitrators to be nominated by Sanofi and BMS fail to agree upon a third arbitrator within
thirty (30) days of the nomination of the second arbitrator, the third arbitrator shall be appointed by the ICC Court. The place of arbitration shall be Paris, France and the language of the arbitration shall be English. Notwithstanding any

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 10 

 
provision to the contrary in the ICC Rules of Arbitration, each Party shall bear its own costs and expenses relating to such arbitration and all related proceedings, including fees for legal
representation. Each Party shall continue to perform its respective obligations under this Agreement and this Agreement shall remain in effect while the Dispute is being resolved. The Parties agree that any dispute arising out of or relating to this
Agreement, the Definitive Agreement, or the Settlement Agreement (including the China Opt-Out Letter) or any Alliance Agreement (as such terms are defined in the Definitive Agreement) shall be resolved in a single arbitration before the ICC,
regardless of how many parties or agreements are implicated, and specifically waive any argument that a dispute arising out of or relating to this Agreement shall be resolved in multiple arbitrations before the ICC. 

7.4 Specific Performance. Each Party agrees that the Developed Know-How is unique, and each Party hereby acknowledges and agrees
that it and the other Parties would be damaged irreparably if any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached. Accordingly, each Party shall be entitled to seek specific
performance and/or interim relief, and agrees that the arbitral tribunal constituted under Section 7.3(b) shall have the power to order specific performance or grant provisional, interim, or conservatory measures, including but not limited to
provisional injunctive relief. The Parties undertake to comply forthwith with any such provisional, interim, or conservatory measures ordered by the arbitral tribunal and agree that such measures may, to the extent not precluded by applicable law,
be enforceable as a final award in any court of competent jurisdiction. For the avoidance of doubt, nothing in this provision shall prevent any Party from seeking conservatory or interim measures, including, but not limited to, temporary restraining
orders or preliminary injunctions or their equivalent, from any court of competent jurisdiction before the arbitral tribunal is constituted under Section 7.3(b) or, thereafter, upon the order of the arbitral tribunal. 

7.5 No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the Parties and
permitted sub-licensees and assigns, and nothing herein, express or implied, is intended to, or shall confer upon, any other Person any legal or equitable right, benefit or remedy of any nature whatsoever. 

7.6 Assignment. 
 (a) None of the Parties hereto may assign any of its rights or obligations to a Third Party under this Agreement without the prior written consent of the other Parties and any assignment without such
consent shall be null and void and of no effect. Each Party may assign any of its rights or obligations under this Agreement to an Affiliate of such Party without the written consent of the other Parties, provided that the assigning Party shall
remain liable for its Affiliate’s performance hereunder. 
 (b) In no event shall the Licensee or its Affiliates be
restricted in their ability to appoint distributors for Products or to sublicense their rights hereunder in accordance with the terms hereof, so long as such appointment or sublicensing does not or would not reasonably be expected to result in an
assignment in violation of this Section 7.6. Notwithstanding the foregoing, Sanofi and its Affiliates shall be permitted to assign this Agreement without BMS’s consent in connection with any divestiture permitted under Section 12.7 of
the Definitive Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 11 

 7.7 Severability. If any term or other provision hereof is held to be invalid,
illegal or incapable of being enforced by applicable law or public policy, all other terms and provisions hereof shall nevertheless remain in full force and effect so long as the economic effect or legal substance of the transactions contemplated
hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so
as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 

7.8 Waivers and Amendments. No modification of or amendment to this Agreement shall be valid unless in a writing signed by the
Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same. Any waiver of any term or condition of this Agreement shall be in a writing signed by the Party sought to be charged with such
waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed to constitute the waiver of any other breach of the same or of any other provision hereof. 

7.9 Headings. All titles and captions contained in this Agreement are for the convenience of reference only and shall not affect
in any way the meaning or interpretation hereof. 
 7.10 Entire Agreement. This Agreement constitutes the entire
agreement of the Parties with respect to the subject matter contained herein and all prior agreements relative thereto which are not contained herein are hereby terminated. 
 7.11 No Partnership or Joint Venture. This Agreement is not intended to create, and nothing contained herein shall be construed to create an association, joint venture, trust or partnership, or to
impose a trust or partnership covenant, obligation or liability on or with regard to the other Party. Each Party shall be severally responsible for its own covenants, obligations and liabilities as herein provided. Other than the Licensee:
(i) no Party shall be under the control of, or shall be deemed to control any other Party; (ii) no Party is the legal representative, agent, joint venturer or employee of the other Party with respect to this Agreement for any purpose
whatsoever, and no Party shall have the right or power to bind the other Party; and (iii) no Party has the right or authority to assume or create any obligations of any kind or to make any representation or warranty on behalf of any other
Party, whether express or implied, or to bind any other Party in any respect whatsoever. The provisions of this Agreement are intended only for the regulation of relations between the Parties. This Agreement is not intended for the benefit of
non-Party creditors, and no rights are granted to non-Party creditors under this Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 12 

 7.12 Governing Language. The Parties acknowledge that this Agreement may be
translated into the French language. The Parties agree that this English language version shall in all respects be the controlling version of this Agreement. 
 7.13 Counterparts. This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original, but all of which when taken together shall constitute
one and the same agreement. 
 7.14 Force Majeure. No Party shall be in default under this Agreement, or shall have any
obligation to the other Party, if such Party is unable to perform under this Agreement by reason of act of God, fire, flood, strike, national emergency or other contingency beyond its reasonable control (a “Force Majeure”). Such
Party shall give the other Party prompt notice of any interruption of performance on account of Force Majeure, and of the resumption of such performance, and shall keep the other Party informed on a current basis as to the steps being taken to
remove, and the anticipated time of removal of, the circumstances resulting in such Force Majeure. Notwithstanding the foregoing, nothing in this Section 7.14 shall excuse or suspend the obligation to make any payment due under this Agreement
in the manner and at the time provided herein. 
 7.15 Definitive Agreement. For so long as (i) BMS is a party to
this Agreement and (ii) the Definitive Agreement remains in effect, in the event of any conflict or inconsistency between any provision of this Agreement and the terms of the Definitive Agreement, the Definitive Agreement shall govern with
respect to such provision. 
 [Remainder of Page Intentionally Left Blank] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 13 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year
first written above. 
  

									
	SANOFI	 		 	SANOFI-AVENTIS U.S. LLC
					
	By:	 	/s/ T. Saugier	 		 	By:	 	/s/ T. Saugier
		 	Name: T. Saugier	 		 		 	Name: T. Saugier
		 	Title: Authorized representative	 		 		 	Title: Authorized representative

  

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	/s/ Katherine Kelly
		 	Name: Katherine Kelly
		 	Title: Assistant Secretary

 [Signature Page to Amended and Restated Territory B1 Know-How License] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 1A 

TERRITORY
B11 

With respect to Irbesartan Products and Clopidogrel Products: 
 Argentina 
 Australia 

Brazil 
 Canada

 Mexico 
 With
respect to Clopidogrel Products only: 
 Colombia 

 

	1 	Territory B1 will be deemed to include any country created by the division, consolidation or name change of the countries listed below. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONEX-10.aa

 Exhibit 10aa 
 *Confidential Treatment Requested 
 ASSIGNMENT AGREEMENT

 This ASSIGNMENT AGREEMENT (this “Agreement”) dated as of January 1, 2013, is hereby made by and
among: Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, a Delaware partnership (“JVB”); Sanofi, a société anonyme organized and existing under the laws of the French Republic
(“Sanofi”); Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware (“BMS”); and sanofi-aventis U.S. LLC, a limited liability company organized and existing under
the laws of the State of Delaware (“Assignee”, and together with JVB, BMS and Sanofi, the “Parties” and each, individually, a “Party”). 

W I T N E S S E T H: 
 WHEREAS, Sanofi previously discovered and patented two new chemical entities, one known as SR 47436 with the international non-proprietary name Irbesartan (“Irbesartan”) and one
known as SR 25990C with the international non-proprietary name Clopidogrel Hydrogenosulphate (“Clopidogrel”); 

WHEREAS, Sanofi, BMS and Sterling Winthrop Inc., a Delaware corporation (“Sterling”) entered into a Development
Agreement dated July 29, 1993 (the “Development Agreement”) for, among other things, the development of Irbesartan and Clopidogrel; 
 WHEREAS, pursuant to an Amended and Restated Asset Purchase Agreement dated as of September 30, 1994 among Eastman Kodak Company, Sanofi and Sterling, Sanofi acquired certain assets, and
assumed certain obligations, of the ethical pharmaceutical business of Sterling, including the rights and obligations of Sterling under the Development Agreement; 
 WHEREAS, Sanofi and BMS have formed JVB through their indirect wholly owned subsidiaries for, among other things, the commercialization of the Products in Territory B (as such terms are defined
herein); 
 WHEREAS, Sanofi and BMS have developed certain know-how under the Development Agreement for the
commercialization of the Products in certain countries, including Territory B; 
 WHEREAS, Sanofi and JVB have entered
into an Irbesartan Intellectual Property License Agreement (the “Territory B Irbesartan License Agreement”) and a Clopidogrel Intellectual Property License and Supply Agreement (the “Territory B Clopidogrel License
Agreement”), each dated as of January 1, 1997, pursuant to which Sanofi granted to JVB a license to use certain patents, trademarks and know-how that neither were developed with nor are owned by BMS, for the commercialization of the
Products in Territory B; 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 WHEREAS, Sanofi, BMS and JVB have entered into a Product Know-How License Agreement
(the “Territory B Know-How License Agreement”), dated as of January 1, 1997, pursuant to which Sanofi and BMS granted to JVB a license under the Developed Know-How (as defined in the Territory B Know-How License Agreement) for
the commercialization of the Products in Territory B; 
 WHEREAS, pursuant to a master restructuring agreement (the
“Master Agreement”), dated as of September 27, 2012, by and between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to
(i) Irbesartan Products (as defined herein) worldwide (other than in Japan, which is not in their alliance) and (ii) Clopidogrel Products (as defined herein) worldwide (other than in Japan, which is not in their alliance, and in the United
States); and 
 WHEREAS, in connection with the transactions contemplated by the Master Agreement, Sanofi and BMS have
agreed to, among other things, assign and transfer JVB’s rights and obligations under the Territory B Irbesartan License Agreement, the Territory B Clopidogrel License Agreement and the Territory B Know-How License Agreement (collectively, the
“Territory B License Agreements”), in each case, solely with respect to Territory B1, to Assignee. 
 NOW,
THEREFORE, in consideration of the mutual covenants and promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows:

  

	 	1.	Definitions 

  

	 	a)	Defined Terms 

“Affiliate,” when used with reference to any Person, means any other Person controlling, controlled by, or under common control with,
such Person; provided, however, that, with respect to Sanofi, the definition of Affiliate shall exclude L’Oréal, a société anonyme organized and existing under the laws of the French Republic. For the purposes of
this definition, “control” shall refer to (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person or to veto any material decision relating to the management or policies of a Person,
in each case whether through the ownership of voting securities, by contract or otherwise; (b) the beneficial ownership, directly or indirectly, of securities (excluding general partnership interests) representing at least 50% of the voting
power of all outstanding voting securities of a Person; or (c) the beneficial ownership of at least 50% of the partnership interests of a general partnership. 
 “Clopidogrel Product” (a) a product with the sole active ingredient Clopidogrel, in finished form, marketed under the trademarks Plavix® and Iscover® or any trademark that is confusingly similar to or that is a replacement for any such trademark; and (b) a product (an “Identified Clopi FDC”)
which contains as the only active ingredients the combination of Clopidogrel with acetylsalicylic acid, in finished form, marketed under the trademarks DuoPlavin®, CoPlavix® and DuoCover® or any trademark that is confusingly similar to or that is a replacement for any such trademark. Clopidogrel
Products shall exclude any other fixed dose combinations containing Clopidogrel. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 2 -

 “IFRS Net Sales” means, with respect to a Product, net sales of Sanofi (or its Affiliates
or their respective licensees or sublicensees) as audited and reported in Euros by Sanofi (or its Affiliates or licensees) in accordance with International Financial Reporting Standards (“IFRS”), as IFRS may be modified from time to
time. For the avoidance of doubt: (a) IFRS Net Sales shall not include samples, compassionate use of the Products and the like; provided that revenue from Products sold to third parties for clinical trial purposes shall be included in
IFRS Net Sales; and (b) any Damages paid by Sanofi pursuant to Article IX of the Master Agreement shall not be treated as a deduction for purposes of calculating IFRS Net Sales. In calculating IFRS Net Sales, the Parties shall disregard any
related Know-How, Discovery or other royalties paid to Sanofi after January 1, 2013 on Clopidogrel Products or Irbesartan Products. 
 “Irbesartan Product” means: (a) a product with the sole active ingredient Irbesartan, in finished form, marketed under the trademarks Aprovel®, Karvea® and Avapro® or any trademark
that is confusingly similar to or that is a replacement for any such trademark; and (b) a product (an “Identified Irbe FDC”) which contains as the only active ingredients the combination of Irbesartan with Hydrochlorothiazide,
in finished form, marketed under the trademarks CoAprovel®, Avalide® and Karvezide® or any trademark that is confusingly similar to or that is a replacement for any such trademark. Irbesartan Products shall exclude any other fixed dose combinations
containing Irbesartan. 
 “New IP Agreement” means the FDC Intellectual Property License Agreement between Sanofi and BMS,
dated as of the date hereof. 
 “Person” means any individual, partnership, firm, corporation, société
anonyme, société en nom collectif, société en participation, société par actions simplifiée, limited liability company, joint venture, association, trust or other entity or
any government or any agency or political subdivision thereof, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the U.S. Securities Exchange Act of 1934, as amended. 

“Product” means a Clopidogrel Product or an Irbesartan Product and “Products” means both a Clopidogrel Product and an
Irbesartan Product. 
 “Territory B” means, with respect to each Territory B License Agreement, “Territory B” as such
term is defined in such Territory B License Agreement prior to amendment thereof in accordance with the terms hereof. 
 “Territory
B1” means (i) with respect to Products, Australia, Canada, Mexico and Argentina, and (ii) with respect to Clopidogrel Products only, also Brazil and Colombia. 
 “United States” means the United States of America, which includes any State or Commonwealth of the United States of America, the District of Columbia, Puerto Rico, the U.S. Virgin
Islands, Guam, American Samoa and any other territory, possession or military base of the United States of America anywhere in the world. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 3 -

	 	b)	Additional Defined Terms. 

 The following
additional defined terms shall have the meanings set forth in the sections of this Agreement listed below: 
  

			
	 Defined Term
	  	 Section Where Defined

	Agreement	  	Preamble
	Assigned Obligations	  	3
	Assigned Rights	  	2
	Assignee	  	Preamble
	BMS	  	Preamble
	Clopidogrel	  	Recitals
	Development Agreement	  	Recitals
	Dispute	  	9
	Dispute Resolution Notice	  	9
	ICC	  	9
	Irbesartan	  	Recitals
	JVB	  	Preamble
	Master Agreement	  	Recitals
	Notices	  	7
	Party	  	Preamble
	Payment Report	  	5(b)
	Payment Term	  	5(a)
	Sanofi	  	Preamble

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 4 -

			
	 Defined Term
	  	 Section Where Defined

	Sterling	  	Recitals
	Territory B Clopidogrel License Agreement	  	Recitals
	Territory B Irbesartan License Agreement	  	Recitals
	Territory B Know-How License Agreement	  	Recitals
	Territory B License Agreements	  	Recitals

  

	 	2.	Assignment  

 JVB hereby sells,
assigns, transfers and conveys to Assignee all of JVB’s right, title and interest in, under and to the Territory B License Agreements, in each case, solely with respect to Territory B1 (collectively, the “Assigned Rights”),
effective as of the date hereof. 
  

	 	3.	Acceptance and Assumption  

Assignee hereby (a) accepts the assignment, transfer and conveyance of the Assigned Rights; and (b) assumes, undertakes and agrees, subject to
valid claims and defenses, to fully and faithfully satisfy, perform and discharge in accordance with the terms of the Territory B License Agreements, as applicable, all obligations and liabilities of any kind arising out of, or required to be
performed under, such Territory B License Agreements, in each case, solely with respect to Territory B1 (collectively, the “Assigned Obligations”). 
  

	 	4.	Amendment and Restatement of License Agreements; Reservation of Rights with respect to Fixed-Dose Combination Products 

 

	a)	Amendment and Restatement of License Agreements. Immediately following assignment and assumption of the Assigned Rights and the Assigned Obligations pursuant to
Sections 2 and 3 hereof, the Parties hereby agree that (i) that portion of the Territory B Clopidogrel License Agreement remaining in place between Sanofi and JVB shall be amended and restated as set forth on Exhibit A hereto,
(ii) that portion of the Territory B Know-How License Agreement remaining in place between Sanofi, BMS and JVB shall be amended and restated as set forth on Exhibit B hereto, and (iii) that portion of the Territory B Know-How
License Agreement assigned to Assignee hereunder shall be amended and restated as set forth on Exhibit C hereto, in each case, effective as of the date hereof and without the need for any further action by any Party or Parties to effect such
amendments and restatements. 

  

	b)	Fixed Dose Combination Products. For the avoidance of doubt, the assignment to and the assumption by the Assignee of the Assigned Rights and the Assigned
Obligations hereunder, shall not affect or limit in any way the licenses granted by and to each of Sanofi and BMS under the New IP Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 5 -

	 	5.	Remuneration 

  

	a)	Remuneration Rates. In consideration of the transfer of the Assigned Rights to Assignee, Sanofi or Assignee shall pay or cause to be paid to JVB, in accordance
with Section 5(b) hereof, the applicable percentage of IFRS Net Sales (as set forth in the tables below) of Sanofi, its Affiliates and their respective licensees of Irbesartan Products and Clopidogrel Products in Territory B1 between
January 1, 2013 and December 31, 2018 (the “Payment Term”). 

  

													
	 	  	2013	 	2014	 	2015	 	2016	 	2017	 	2018
	 Clopidogrel (% of IFRS Net Sales):
	  	[*]	 	[*]	 	[*]	 	[*]	 	[*]	 	[*]

  

													
	 	  	2013	 	2014	 	2015	 	2016	 	2017	 	2018
	 Irbesartan (% of IFRS Net Sales):
	  	[*]	 	[*]	 	[*]	 	[*]	 	[*]	 	[*]

  

	b)	Payment Provisions. 

  

	 	i.	The amounts payable to JVB pursuant to Section 5(a) hereof shall not be subject to any generic penetration/market share or parallel trade adjustments (and any
changes in such percentages in the table above from one year to the next shall be with effect as of January 1 of the year in which the new percentage applies). 

 

	 	ii.	For the Payment Term, Sanofi or Assignee shall pay or cause to be paid to JVB all amounts due hereunder on a quarterly basis within sixty (60) days of the end of
each calendar quarter. Each such payment shall be accompanied by an accurate statement of: (a) the amount of IFRS Net Sales of the Products (denominated in Euros), set forth on a [*], relating to payments to be made to JVB during such calendar
quarter (together with the underlying calculations in reasonable detail for such amount); (b) the remuneration payments due to JVB under this Agreement set forth on a [*]; and (c) the calculation of all payments to be made to JVB for such
calendar quarter (each a “Payment Report”). The remuneration amount shall be declared in Euros based on IFRS Net Sales and shall be paid to JVB in U.S. dollars and converted from Euros to U.S. dollars at the Designated Exchange Rate
applicable for the month in which the payment is made. The “Designated Exchange Rate” means the exchange rate applicable for each calendar month based on the prior month’s daily average EUR/USD rate set by the European Central Bank
each day. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 6 -

	 	iii.	All payments to be made hereunder shall be made by wire transfer in immediately available funds, to the bank account of JVB as designated in writing to Sanofi by JVB,
unless the Parties agree to settle such payments through other means. 

  

	 	iv.	All payments due under this Agreement shall be paid in full without deduction, except for taxes (if any) required to be withheld by applicable law with respect to such
payments. In the event Sanofi or Assignee is required under applicable law to withhold any tax to the revenue authorities in any country regarding any payment to JVB, the amount of such tax shall be deducted by Sanofi or Assignee (as applicable) and
paid to the relevant revenue authority, and Sanofi or Assignee shall notify JVB thereof and shall promptly furnish to JVB all copies of any tax certificate or other documentation evidencing such withholding. If any such tax shall subsequently be
found to be due, payment of such tax shall be the responsibility of JVB. Notwithstanding the foreoing, BMS and Sanofi shall cooperate reasonably to reduce or eliminate any such withholding tax under applicable law or treaty.

  

	 	6.	Parties in Interest 

 This
Agreement shall be binding upon and inure solely to the benefit of the Parties and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable
right, benefit or remedy of any nature whatsoever. 
  

	 	7.	Notices 

 All notices, requests or
other communications hereunder (collectively, “Notices”) shall be in writing, shall be in the English language and shall be given or made by delivery in person, by courier service, by facsimile (with receipt confirmed) or by
registered or certified mail (return receipt requested, with postage prepaid) to the respective Parties at the following addresses: 
 If to Sanofi, to: 
 Sanofi 

54, rue la Boétie 
 75008 Paris, France 
 Attention: Senior Vice President, Legal
Affairs and General Counsel 
 Facsimile: (33.1) 53.77.43.03 

Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 7 -

 with a copy to: 

Weil Gotshal & Manges 
 767 Fifth Avenue 
 New York, NY 10153 

Attention: [omitted] 
 Facsimile: 212-310-8007 
 If to BMS, to: 

Bristol-Myers Squibb Company 
 P.O. Box 4000 
 Route 206 & Province Line Road

 Princeton, NJ 08543-4000 USA 
 Attention: Vice President and Senior Counsel, Pharmaceutical Research Institute, and Worldwide 
   Franchise Management and Business Development 
 Facsimile:
649-252-4232 
 Attention: Vice President, Alliance Management 

Facsimile: 609-252-7235 
 with a copy to: 
 Wilmer Cutler Pickering Hale and Dorr LLP

 7 World Trade Center 

New York, NY 10007 USA 
 Facsimile: 212-230-8888 
 Attn: [omitted] 

If to JVB, to: 
 Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership 

P.O. Box 4000 
 Route 206 & Province Line Road 
 Princeton, NJ 08543-4000
USA 
 Attention: Vice President and Senior Counsel, Pharmaceutical Research Institute, and Worldwide 

  Franchise Management and Business Development 
 Facsimile: 649-252-4232 
 Attention: Vice President, Alliance Management

 Facsimile: 609-252-7235 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 8 -

 with a copy to: 

Sanofi 
 54, rue la Boétie 
 75008 Paris, France 

Attention: Senior Vice President, Legal Affairs and General Counsel 

Facsimile: (33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 
 If to Assignee, to: 
 sanofi-aventis U.S. LLC 

55 Corporate Drive 
 Bridgewater, NJ 08807 USA 
 Attention: [omitted] 

Facsimile: (908) 981-5705 
 with a copy to: 
 sanofi-aventis U.S. LLC 

55 Corporate Drive 
 Bridgewater, NJ 08807 USA 
 Attention: [omitted] 

Facsimile: (908) 981-7833 
 and 
 Weil Gotshal & Manges 

767 Fifth Avenue 
 New York, NY 10153 
 Attention: [omitted] 

Facsimile: 212-310-8007 
  

	 	8.	Governing Law  

 This Agreement
shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts executed and performed entirely in that state, without regard to any principles of conflicts of laws thereof. 

 

	 	9.	Dispute Resolution 

  

	a)	 Negotiation and Notice. In the event of any dispute, claim, controversy or disagreement (each, a “Dispute”) arising out of, in
connection with or relating to this Agreement, including any question regarding this Agreement’s existence, validity or termination, the Parties shall 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 9 -

	 	
first seek resolution of such Dispute by negotiation between their respective senior management. Such negotiation shall be deemed to commence upon the service by either Party upon the other of a
written notice (a “Dispute Resolution Notice”) under this Section 9(a). 

  

	b)	Arbitration. If a Dispute subject to negotiation under Section 9(a) is not finally resolved within thirty (30) days following receipt by one Party of a
Dispute Resolution Notice, the Dispute shall be finally resolved by arbitration under the Rules of Arbitration of the International Chamber of Commerce (the “ICC”). The arbitral tribunal shall be composed of three
(3) arbitrators. Each Party shall nominate one (1) arbitrator. The two arbitrators so nominated shall nominate the presiding arbitrator. If either Party fails to nominate an arbitrator in its Request for Arbitration or within thirty
(30) days of receiving written notice of the nomination of an arbitrator by the other Party, such arbitrator shall be appointed by the ICC Court. If the two (2) arbitrators to be nominated by the Parties fail to agree upon a third
arbitrator within thirty (30) days of the nomination of the second arbitrator, the third arbitrator shall be appointed by the ICC Court. The place of arbitration shall be Paris, France and the language of the arbitration shall be English.
Notwithstanding any provision to the contrary in the ICC Rules of Arbitration, each Party shall bear its own costs and expenses relating to such arbitration and all related proceedings, including fees for legal representation. Each Party shall
continue to perform its respective obligations under this Agreement and this Agreement shall remain in effect while the Dispute is being resolved. 

  

	 	10.	Severability 

 If any term or other
provision hereof is held to be invalid, illegal or incapable of being enforced by applicable law or public policy, all other terms and provisions hereof shall nevertheless remain in full force and effect so long as the economic effect or legal
substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate
in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest
extent possible. 
  

	 	11.	Waivers and Amendments  

 No
modification of or amendment to this Agreement shall be valid unless in a writing signed by the Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same. Any waiver of any term or condition
of this Agreement shall be in a writing signed by the Party sought to be charged with such waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed to constitute the waiver of any other breach of the
same or of any other provision hereof. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 10 -

	 	12.	Headings 

 All titles and captions
contained in this Agreement are for the convenience of reference only and shall not affect in any way the meaning or interpretation hereof. 
  

	 	13.	Counterparts  

This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original, but all of which when taken
together shall constitute one and the same agreement. 
 [The remainder of this page is intentionally left blank.]

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 - 11 -

 IN WITNESS WHEREOF, the Parties hereto have duly executed and delivered this Agreement as of
the date first written above. 
  

			
	SANOFI
		
	By:	 	/s/ T. Saugier
		 	 Name: T. Saugier
 Title:
Authorized representative

  

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	/s/ Katherine Kelly
		 	 Name: Katherine Kelly

Title: Assistant Secretary

 BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP 

 

			
	 Represented by:
  

BRISTOL-MYERS SQUIBB INVESTCO, L.L.C.

		
	By:	 	/s/ Katherine Kelly
		 	 Name: Katherine Kelly

Title: Secretary

  

			
	 Witnessed by:
  

SANOFI-AVENTIS U.S. LLC

		
	By:	 	/s/ T. Saugier
		 	 Name: T. Saugier
 Title:
Authorized representative

  

			
	SANOFI-AVENTIS U.S. LLC
		
	By:	 	/s/ T. Saugier
		 	 Name: T. Saugier
 Title:
Authorized representative

 [Signature Page to B1 Assignment Agreement] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 EXHIBIT A 
 Amended and Restated Territory B Clopidogrel License Agreement 
 See form attached
as Exhibit 2.1(a)(ii) to the Master Agreement 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 EXHIBIT B 
 Amended and Restated Territory B Know-How License Agreement 
 See form attached as
Exhibit 2.1(a)(iii) to the Master Agreement 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 EXHIBIT C 
 Amended and Restated Territory B1 Know-How License Agreement 
 See form attached as
Exhibit 2.1(a)(iv) of the Master Agreement 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]